Board


Screen Shot 2016-09-18 at 19.44.47.png

Malcolm Bell - Non-executive Director

Malcolm co-founded Technopath Clinical Diagnostics in 2004 and was appointed CEO in 2011. He has successfully co-founded, developed and exited a number of life science and healthcare businesses based on novel technology and drawing on his over 20 years’ experience in these sectors. Malcolm brings extensive sales experience to the Company based on his strong scientific background. Malcolm identified the market need and initially led the project to develop the Valitacell technology. Previously, Malcolm was the co-founder and Joint Managing Director of Technopath (Distribution) which is now part of the Diploma plc group. Malcolm was educated at the National University of Ireland and holds a B.Sc. Honours degree in Molecular Biology and a Master's Degree in Biotechnology.

 

Jerry Clifford - COO

Prior to establishing Valitacell Jerry worked as the Commercial Director of Technopath Ltd (2010-2014). In this role he initiated and defined the research programme with the University of Sheffield which led to the development of the Valitacell technologies and the associated IP. The Technopath Group grew significantly during his time there, including achieving a sole supplier contract with a major IVD company. A trade-sale exit of Technopath Distribution to Diploma Healthcare followed in September 2014. Prior to Technopath Jerry was Vice President for Development at the Institute of Technology Tralee. He is a founder and a Non-Executive Director of Castel International, a provider of English Language and concierge services to a number of Irish universities and medical training colleges. Jerry trained as neuroscientist and holds a PhD from RCSI and an MBA from UCC.

 

Terry McWade - CEO

Terry worked in the pharmaceutical industry with Servier Laboratories as Managing Director of Servier Denmark and previously in the Paris headquarters (1988-1992). He led the healthcare consulting practice in the London office of the Boston Consulting Group (1993-1999). As CEO of Exceptis Technologies, Terry led the sale of the business to Trintech Group (TTPA nasdaq) for $26m in 2000. Prior to establishing Valitacell Terry was Deputy CEO of the Royal College of Surgeons in Ireland (2002-2013). He is the former Chairman of the European Vaccine Initiative, Deputy Chairman of the Dublin Dental Hospital and serves on a number of committees of the Irish Medical Council. Terry trained as a medical doctor in Trinity College Dublin and holds an MBA from INSEAD.

 

Dave Sullivan - Non-Executive Director

Co-founder of Technopath Group, and CEO of Technopath Distribution since 2011, David is an experienced CEO and sales and marketing professional with a demonstrated track record of identifying, launching and growing new product lines in the life sciences arena over his 25 year career. Since co-founding the company in 1997 he has consistently grown the business exponentially. An EY Entrepreneur of the Year Finalist, David has developed and launched a number of life science technologies and businesses. Earlier in his career David worked for Brennan & Company as Product Manager for Beckman DSG from 1989 and as Sales Manger for the Clinical Division from 1992-1998, managing major multinational brands including, Beckman DSG, Instrumentation Laboratory and Ortho Clinical Diagnostics. David is a Fellow of the Institute of Medical Laboratory Sciences, from University of the West of England in 1988, having previously graduated with a a Certificate and Diploma in Medical Laboratory Sciences from Cork Institute of Technology in 1984 and 1986 respectively.

 
dave sullivan.png

Peter Thornton - Non-Executive Director

Peter is CFO and an investor in Technopath Clinical Diagnostics since 2014. He brings significant experience in the areas of finance, corporate development and M&A in both public and private life science companies. He most recently served as SVP Business Integration for Alkermes plc, SVP Corporate and Business Development for Elan Corporation plc and CFO of Agenus Inc., a NASDAQ-listed biotechnology company. Peter has served as a Director of both public and private companies including Merrion Pharmaceuticals plc, Cydex Pharmaceuticals Inc. and Agenus Inc. and is currently a director of Munich based drug delivery company Leon Nanodrugs Gmbh. Peter is a KPMG qualified Chartered Accountant and holds a Bachelor o f Commerce degree from University College Cork, Ireland.